Kuros Biosciences Inaugurates New US Site

Schlieren, ZH/Alpharetta — Kuros Biosciences AG, based in Schlieren, marks the first step toward commissioning a new plant in the US with a symbolic ribbon-cutting ceremony. The official opening will follow in July 2026.

According to a press release, Kuros Biosciences took the “first step” in its US expansion by cutting the ribbon at its new production site in Alpharetta, Georgia.

As announced in August, Kuros Biosciences will establish its new US headquarters in Alpharetta. In addition to facilities for producing the bone substitute MagnetOs, the site will also have office space. Once construction is complete, the new headquarters will begin operations in July 2026. Kuros Biosciences plans to create 50 jobs there over the next three years.

Kuros Biosciences is a spin-off of the University of Zurich (UZH) and the Swiss Federal Institute of Technology Zurich (ETHZ). The company is currently based in the Bio-Technopark Schlieren-Zurich.

(Source: punkt4 Limmattal <limmatstadt@punkt4.info>)